Posterisan Escherichia coli bacterial suspension/hydrocortisone compound hemorrhoid ointment 2g x 50 tubes strong Posterisan forte strong hemorrhoid ointment

Hydrocortisone compound hemorrhoid ointment is used to treat hemorrhoids (bleeding, pain, swelling, itching), anal surgical wounds, perianal eczema and dermatitis.

I. Basic Drug Information

1. Generic Name : Hemorrhoid Treatment Agent
2. English name : Posterisan forte
3. Product Name : Power Enhancer (Ointment)
4. Dosage form : Ointment
5. Indications :
   • The symptoms of hemorrhoids and anal fissures (bleeding, pain, swelling, itching) are relieved.
   • Symptoms related to anal surgery wounds were relieved.
   • Symptoms of eczema and dermatitis around the anus have been relieved.
   • Symptoms of mild proctitis have been relieved.
6. Element :
   • Active ingredients : Each 1g ointment contains 0.163mL of dead Escherichia coli suspension (containing approximately 259 million dead Escherichia coli) and 2.5mg of hydrocortisone.
   • Additives : refined lanolin, white petrolatum, liquid paraffin.
7. Characteristics :
   • Dead Escherichia coli suspension: a yellowish-grayish-white to yellowish-grayish-brown suspension with the odor of liquid paraffin.
   • Hydrocortisone: a white crystalline powder, slightly soluble in methanol or ethanol (99.5%), and extremely soluble in water.
   • The overall properties of the formulation are not clearly described in detail.

II. Usage and Dosage

• If using a 2g tubing, when inserting it into the anus, only insert the nozzle portion; do not insert the entire container.
• This medicine is not for ophthalmic use.

III. Taboos

1. Patients with localized tuberculous, purulent infections, or viral diseases: The hydrocortisone contained in this medication may worsen these conditions.
2. Patients with localized fungal infections (candidiasis, tinea, etc.): The hydrocortisone contained in this medication may worsen the fungal infection.
3. Patients with a history of allergy to this drug.
4. Patients with a history of allergy to hydrocortisone.

IV. Precautions

1. Special populations
   • Pregnant women : Use only when the benefits of treatment outweigh the risks; avoid large doses or prolonged use.
   • For breastfeeding mothers : The benefits of treatment and the nutritional benefits of breast milk should be considered together before deciding whether to continue or stop breastfeeding.
   • Children, etc .: Reports indicate that large or long-term use of steroid drugs may lead to developmental disorders, so special attention should be paid to avoid long-term use.
   • Elderly patients : The patient's condition needs to be observed when administering the medication, as elderly patients are generally more prone to side effects.
2. Medication guidance
   • In principle, this drug should not be used when there is a local infection or fungal infection; if it must be used, appropriate antibacterial or antifungal agents should be used first, or combination therapy with these drugs should be considered.
   • Prolonged continuous use may cause symptoms similar to those of systemic medication, and should be avoided.
   • Close observation is necessary during medication use. If any abnormalities occur, appropriate measures such as discontinuing use should be taken.
   • Continuous use may cause increased intraocular pressure, glaucoma, and posterior capsule cataracts. Regular check-ups are recommended.
   • Large doses or long-term use may suppress the function of the pituitary and adrenal cortex systems, so extra caution is required.
3. Drug storage : Store at room temperature.

V. Adverse Reactions

1. Allergic reaction
   • Incidence rate 0.1-5% Incomplete: Itching.
   • Incidence unknown: contact dermatitis, erythema, rash, skin irritation.
2. Digestive system reaction : Incidence 0.1% Incomplete bowel movement: Urgency to defecate.
3. Other adverse reactions
   • Skin: Incidence unknown, fungal infections (candidiasis, tinea, etc.), viral infections, and bacterial infections of the skin and genital area.
   • Eye: Incidence unknown. It can cause retinal disorders and proptosis due to central serous chorioretinopathy, and may also lead to glaucoma and posterior capsule cataract (incidence unknown).
   • Endocrine system: Incidence unknown, but suppressed function of the pituitary and adrenal cortex systems (more likely to occur with high doses or long-term use).
   • Other: Incidence rate 0.1% - Incomplete, discomfort at the applicable site.

VI. Drug Interactions

VII. Pharmacological effects

1. Moderating biofilm function : No information was mentioned regarding the modification of biofilm function.
2. Improvement of metabolic abnormalities : No information was mentioned regarding improvement of metabolic abnormalities.
3. Regulating blood lipids : No information was mentioned regarding regulating blood lipids.
4. Protecting blood vessels : Hydrocortisone has the effect of inhibiting increased vascular permeability, which can protect blood vessels to a certain extent and reduce inflammatory response.
5. Other functions
   • Local infection defense : The suspended liquid of dead Escherichia coli can enhance the migration ability of leukocytes, thereby playing a role in local infection defense (in vitro, mouse experiments).
   • Granulation tissue formation promoting effect : The suspended liquid of dead Escherichia coli promotes granulation tissue formation and accelerates wound healing (rat experiment).
   • Anti-inflammatory effects : Hydrocortisone has anti-inflammatory effects such as inhibiting increased vascular permeability, inhibiting heat inflammation, and inhibiting edema (rat experiments).
   • Synergistic effect : Based on the synergistic effect of dead Escherichia coli suspension and hydrocortisone, this drug exerts local infection defense, granulation tissue formation promotion and anti-inflammatory effects (rat and mouse experiments).

VIII. Pharmacokinetics

1. Absorption : No relevant absorption information was mentioned.
2. Excretion : No relevant excretion information was mentioned.

IX. Clinical Research

(a) Efficacy and safety related trials (domestic clinical studies)

10. Packaging Specifications

• 2g x 50g [5 pieces x 10]
• 2g x 300g [5 pieces x 60g]
• 2g x 350g [7 pieces x 50g]
• 30g×10

XI. Production Information

Manufacturer : Maruho Co. , Ltd.